Epigenetic markers for noninvasive early detection of nasopharyngeal carcinoma by methylation-sensitive high resolution melting

International Journal of Cancer

Volumn 136, Issue 4, 2015, Pages E127-E135

  Yang, Xuesong ^a   Dai, Wei ^a   Kwong, Dora Lai Wan ^a   Szeto, Carol Y Y ^a   Wong, Elibe Hiu Wun ^a   Ng, Wai Tong ^a,b   Lee, Anne W M ^a,c   Ngan, Roger K C ^a,d   Yau, Chun Chung ^a,e   Tung, Stewart Y ^a,f   Lung, Maria Li ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b PAMELA YOUDE NETHERSOLE EASTERN HOSPITAL   (Hong Kong)

^c THE UNIVERSITY OF HONG KONG SHENZHEN HOSPITAL   (China)

^d QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^e PRINCESS MARGARET HOSPITAL   (Hong Kong)

^f TUEN MUN HOSPITAL   (Hong Kong)

Author keywords

Biomarker; DNA methylation; Early diagnosis; MS HRM; NPC

Indexed keywords

RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; TUMOR MARKER;

ADULT; ARTICLE; CANCER STAGING; CARCINOMA IN SITU; CELL FREE SYSTEM; CONTROLLED STUDY; DAPK1 GENE; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE MARKER; DNA METHYLATION; EARLY DIAGNOSIS; EPIGENETICS; FEMALE; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; LOCAL RECURRENCE FREE SURVIVAL; MAJOR CLINICAL STUDY; MALE; METHYLATION SENSITIVE HIGH RESOLUTION MELTING; NASOPHARYNX CARCINOMA; OVERALL SURVIVAL; PREDICTIVE VALUE; PROMOTER REGION; RARB2 GENE; RASSF1A GENE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TUMOR SUPPRESSOR GENE; WIF1 GENE; AGED; BLOOD; CARCINOMA; CASE CONTROL STUDY; GENETIC EPIGENESIS; GENETICS; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; TRANSITION TEMPERATURE; TUMOR CELL LINE;

ADULT; AGED; CARCINOMA; CASE-CONTROL STUDIES; CELL LINE, TUMOR; DNA METHYLATION; EARLY DETECTION OF CANCER; EPIGENESIS, GENETIC; FEMALE; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; PROMOTER REGIONS, GENETIC; ROC CURVE; TRANSITION TEMPERATURE; TUMOR MARKERS, BIOLOGICAL;

EID: 84918526343     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29192     Document Type: Article

References (43)

1. Bhattacharyya N. The impact of race on survival in nasopharyngeal carcinoma: A matched analysis. Am J Otolaryngol 2004;25:94-7
2. McDermott AL, Dutt SN, Watkinson JC. The aetiology of nasopharyngeal carcinoma. Clin Otolaryngol Allied Sci 2001;26:82-92
3. Armstrong RW, Imrey PB, Lye MS, et al. Nasopharyngeal carcinoma in Malaysian Chinese: occupational exposures to particles, formaldehyde and heat. Int J Epidemiol 2000;29:991-8
4. Tao Q, Chan ATC. Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev Mol Med 2007;9:1-24
5. Raab-traub N. Epstein - Barr virus in the pathogenesis of NPC. Semin Cancer Biol 2002;12:431-41
6. Tao Q, Young LS, Woodman CBJ, et al. Epstein- Barr virus (EBV) and its associated human cancers-genetics, epigenetics, pathobiology and novel therapeutics. Front Biosci 2006;11:2672-713
7. Yu MC, Yuan J. Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol 2002;12:421-9
8. Yip TTC, Ngan RKC, Fong AHW, et al. Application of circulating plasma/serum EBV DNA in the clinical management of nasopharyngeal carcinoma. Oral Oncol 2014;50:527-38
9. Lo YMD, Chan ATC, Chan LYS, et al. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res 2000;60:6878-81
10. Chan ATC, Lo YM, Zee B, et al. Plasma Epstein- Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst 2002;94:1614-9
11. Lin J-C, Wang W-Y, Chen KY, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 2004;350:2461-70
12. Le Q-T, Zhang Q, Cao H, et al. An international collaboration to harmonize the quantitative plasma Epstein-Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma. Clin Cancer Res 2013;19:2208-15
13. Chan KCA, Hung ECW, Woo JKS, et al. Early detection of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA analysis in a surveillance program. Cancer 2013;119:1838-44
14. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-54
15. Esteller M, Corn PG, Baylin SB, et al. A gene hypermethylation profile of human cancer. Cancer Res 2001;61:3225-9
16. Dammann R, Li C, Yoon JH, et al. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 2000;25:315-9
17. Chow LS-N, Lo K-W, Kwong J, et al. RASSF1A is a target tumor suppressor from 3p21.3 in nasopharyngeal carcinoma. Int J Cancer 2004;109: 839-47
18. Lo K, Kwong J, Hui AB, et al. High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res 2001;61:3877-81
19. Hu J, Dong A, Fernandez-Ruiz V, et al. Blockade of Wnt signaling inhibits angiogenesis and tumor growth in hepatocellular carcinoma. Cancer Res 2009;69:6951-9
20. Kawakami K, Hirata H, Yamamura S, et al. Functional significance of Wnt inhibitory factor-1 gene in kidney cancer. Cancer Res 2009;69:8603-10
21. Michie AM, McCaig AM, Nakagawa R, et al. Death-Associated protein kinase (DAPK) and signal transduction: regulation in cancer. FEBS J 2010;277:74-80
22. Maruyama R, Toyooka S, Toyooka KO, et al. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 2002;8:514-9
23. Kwong J, Lo K, To K. Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma promoter hypermethylation of multiple genes in. Clin Cancer Res 2002;8:131-7
24. Swarup V, Rajeswari MR. Circulating (cell-free) nucleic acids-A promising, non-invasive tool for early detection of several human diseases. FEBS Lett 2007;581:795-9
25. Chan KCA, Jiang P, Chan CWM, et al. Noninvasive detection of cancer-Associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing. Proc Natl Acad Sci USA 2013;110:18761-8
26. Wong TS, Chang HW, Tang KC, et al. High frequency of promoter hypermethylation of the death-Associated protein-kinase gene in nasopharyngeal carcinoma and its detection in the peripheral blood of patients high frequency of promoter hypermethylation of the death- associated protein-kinase G. Clin Cancer Res 2002;8: 433-7
27. Wong T-S. Quantitative plasma hypermethylated DNA markers of undifferentiated nasopharyngeal carcinoma. Clin Cancer Res 2004;10:2401-6
28. Chang HW, Chan A, Kwong DLW, et al. Evaluation of hypermethylated tumor suppressor genes as tumor markers in mouth and throat rinsing fluid, nasopharyngeal swab and peripheral blood of nasopharygeal carcinoma patient. Int J Cancer 2003;105:851-5
29. Tian F, Yip SP, Kwong DLW, et al. Promoter hypermethylation of tumor suppressor genes in serum as potential biomarker for the diagnosis of nasopharyngeal carcinoma. Cancer Epidemiol 2013;37:708-13
30. Stevens SJC, Verkuijlen SAWM, Hariwiyanto B, et al. Noninvasive diagnosis of nasopharyngeal carcinoma: nasopharyngeal brushings reveal high Epstein-Barr virus DNA load and carcinomaspecific viral BARF1 mRNA. Int J Cancer 2006; 119:608-14
31. Hutajulu SH, Indrasari SR, Indrawati LPL, et al. Epigenetic markers for early detection of nasopharyngeal carcinoma in a high risk population. Mol Cancer 2011;10:48
32. Ng RHW, Ngan R, Wei WI, et al. Trans-oral brush biopsies and quantitative PCR for EBV DNA detection and screening of nasopharyngeal carcinoma. Otolaryngol Head Neck Surg 2014;150: 602-9
33. Lung HL, Bangarusamy DK, Xie D, et al. THY1 is a candidate tumour suppressor gene with decreased expression in metastatic nasopharyngeal carcinoma. Oncogene 2005;24:6525-32
34. Li HM, Man C, Jin Y, et al. Molecular and cytogenetic changes involved in the immortalization of nasopharyngeal epithelial cells by telomerase. Int J Cancer 2006;119:1567-76
35. Ko JMY, Chan PL, Yau WL, Chan HK, Chan KC, Yu ZY, Kwong FM, Miller LD, Liu ET, Yang LC, Lo PHY, Stanbridge EJ, et al. Monochromosome transfer and microarray analysis identify a critical tumor-suppressive region mapping to chromosome 13q14 and THSD1 in esophageal carcinoma. Mol Cancer Res 2008;6:592-603
36. Wojdacz TK, Dobrovic A, Hansen LL. Methylation- sensitive high-resolution melting. Nat Protoc 2008;3:1903-8
37. Wojdacz TK, Borgbo T, Hansen LL. Primer design versus PCR bias in methylation independent PCR amplifications. Epigenetics 2009;4:231-4
38. Huang KT, Dobrovic A, Yan M, et al. DNA methylation profiling of phyllodes and fibroadenoma tumours of the breast. Breast Cancer Res Treat 2010;124:555-65
39. Lo YMD, Chan LYS, Lo K, et al. Quantitative analysis of cell-free Epstein-Barr Virus DNA in plasma of patients with nasopharyngeal carcinoma advances in brief quantitative analysis of cell-free Epstein-Barr Virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 1999;59:1188-91
40. Lo K, Kwong J, Hui AB, et al. High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res 2001;61:3877-81
41. Fendri, Ali, Gargouri A, Mokdad-gargouri R. Inactivation of RASSF1A, RARb2 and DAPkinase by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma. Cancer Biol Ther 2009;8:1-8
42. Chan SL, Cui Y, van Hasselt A, et al. The tumor suppressor Wnt inhibitory factor 1 is frequently methylated in nasopharyngeal and esophageal carcinomas. Lab Invest 2007;87:644-50
43. Kristensen LS, Hansen LL. PCR-based methods for detecting single-locus DNA methylation biomarkers in cancer diagnostics, prognostics, and response to treatment. Clin Chem 2009;55:1471-83.